

**Table 2A: Consensus guidelines on immunomodulatory therapy in times of COVID-19 in High risk patients – As per years of experience and uveitis patients per year**

			Uveitis specialists' expertise		Healthy patient – without contact	Healthy patient – with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
<b>ORAL CORTICOSTEROIDS</b>	Patient not on oral corticosteroids	To be started	Years of experience in uveitis	≤ 15 (n = 80)	56 ( 70 % )	24 ( 30 % )	5 ( 6.25 % )	3 ( 3.75 % )
				> 15 (n = 59)	42 ( 71.19 % )	19 ( 32.2 % )	2 ( 3.39 % )	2 ( 3.39 % )
			Uveitis patients on IMT/year	< 300 (n = 85)	61 ( 71.76 % )	27 ( 31.76 % )	5 ( 5.88 % )	4 ( 4.71 % )
				≥ 300 (n =54)	37 ( 68.52 % )	16 ( 29.63 % )	2 ( 3.7 % )	1 ( 1.85 % )
	Patient on low dose oral corticosteroids	To be maintained	Years of experience in uveitis	≤ 15 (n = 80)	74 ( 92.5 % )	38 ( 47.5 % )	18 ( 22.5 % )	13 ( 16.25 % )
				> 15 (n = 59)	55 ( 93.22 % )	39 ( 66.1 % )	18 ( 30.51 % )	15 ( 25.42 % )
			Uveitis patients on IMT/year	< 300 (n = 85)	80 ( 94.12 % )	49 ( 57.65 % )	22 ( 25.88 % )	15 ( 17.65 % )
				≥ 300 (n =54)	49 ( 90.74 % )	28 ( 51.85 % )	14 ( 25.93 % )	13 ( 24.07 % )
		To be decreased	Years of experience in uveitis	≤ 15 (n = 80)	16 ( 20 % )	48 ( 60 % )	62 ( 77.5 % )	67 ( 83.75 % )
				> 15 (n = 59)	6 ( 10.17 % )	27 ( 45.76 % )	41 ( 69.49 % )	44 ( 74.58 % )
			Uveitis patients on IMT/year	< 300 (n = 85)	9 ( 10.59 % )	43 ( 50.59 % )	60 ( 70.59 % )	66 ( 77.65 % )
				≥ 300 (n =54)	13 ( 24.07 % )	32 ( 59.26 % )	43 ( 79.63 % )	45 ( 83.33 % )
		To be tapered and stopped	Years of experience in uveitis	≤ 15 (n = 80)	11 ( 13.75 % )	40 ( 50 % )	60 ( 75 % )	66 ( 82.5 % )
				> 15 (n = 59)	5 ( 8.47 % )	22 ( 37.29 % )	38 ( 64.41 % )	39 ( 66.1 % )
			Uveitis patients on IMT/year	< 300 (n = 85)	7 ( 8.24 % )	35 ( 41.18 % )	61 ( 71.76 % )	65 ( 76.47 % )
				≥ 300 (n =54)	9 ( 16.67 % )	27 ( 50 % )	37 ( 68.52 % )	40 ( 74.07 % )
	Patient on higher dose oral corticosteroids	To be maintained	Years of experience in uveitis	≤ 15 (n = 80)	46 ( 57.5 % )	24 ( 30 % )	9 ( 11.25 % )	6 ( 7.5 % )
				> 15 (n = 59)	40 ( 67.8 % )	19 ( 32.2 % )	8 ( 13.56 % )	4 ( 6.78 % )
			Uveitis patients on IMT/year	< 300 (n = 85)	56 ( 65.88 % )	28 ( 32.94 % )	13 ( 15.29 % )	6 ( 7.06 % )
				≥ 300 (n =54)	30 ( 55.56 % )	15 ( 27.78 % )	4 ( 7.41 % )	4 ( 7.41 % )
To be decreased		Years of experience in uveitis	≤ 15 (n = 80)	40 ( 50 % )	59 ( 73.75 % )	71 ( 88.75 % )	74 ( 92.5 % )	
			> 15 (n = 59)	23 ( 38.98 % )	37 ( 62.71 % )	52 ( 88.14 % )	54 ( 91.53 % )	
		Uveitis patients on IMT/year	< 300 (n = 85)	33 ( 38.82 % )	54 ( 63.53 % )	72 ( 84.71 % )	77 ( 90.59 % )	
			≥ 300 (n =54)	30 ( 55.56 % )	42 ( 77.78 % )	51 ( 94.44 % )	51 ( 94.44 % )	
To be tapered	Years of experience	≤ 15 (n = 80)	23 ( 28.75 % )	46 ( 57.5 % )	65 ( 81.25 % )	72 ( 90 % )		

		and stopped	in uveitis	> 15 (n = 59)	11 ( 18.64 % )	24 ( 40.68 % )	45 ( 76.27 % )	46 ( 77.97 % )	
			Uveitis patients on IMT/year	< 300 (n = 85)	20 ( 23.53 % )	40 ( 47.06 % )	67 ( 78.82 % )	75 ( 88.24 % )	
				≥ 300 (n =54)	14 ( 25.93 % )	30 ( 55.56 % )	43 ( 79.63 % )	43 ( 79.63 % )	
<b>IV METHYL PREDNISOLONE</b>		To be started	Years of experience in uveitis	≤ 15 (n = 80)	41 ( 51.25 % )	15 ( 18.75 % )	5 ( 6.25 % )	4 ( 5 % )	
				> 15 (n = 59)	32 ( 54.24 % )	10 ( 16.95 % )	2 ( 3.39 % )	2 ( 3.39 % )	
			Uveitis patients on IMT/year	< 300 (n = 85)	45 ( 52.94 % )	15 ( 17.65 % )	4 ( 4.71 % )	3 ( 3.53 % )	
				≥ 300 (n =54)	28 ( 51.85 % )	10 ( 18.52 % )	3 ( 5.56 % )	3 ( 5.56 % )	
<b>LOCAL CORTICOSTEROIDS</b>	Patient not on oral corticosteroids	To be preferred to systemic therapy	Years of experience in uveitis	≤ 15 (n = 80)	59 ( 73.75 % )	70 ( 87.5 % )	70 ( 87.5 % )	69 ( 86.25 % )	
				> 15 (n = 59)	42 ( 71.19 % )	52 ( 88.14 % )	53 ( 89.83 % )	53 ( 89.83 % )	
			Uveitis patients on IMT/year	< 300 (n = 85)	63 ( 74.12 % )	74 ( 87.06 % )	72 ( 84.71 % )	72 ( 84.71 % )	
				≥ 300 (n =54)	38 ( 70.37 % )	48 ( 88.89 % )	51 ( 94.44 % )	50 ( 92.59 % )	
	Patient on low dose oral corticosteroids	To be preferred to increasing systemic therapy	Years of experience in uveitis	≤ 15 (n = 80)	62 ( 77.5 % )	72 ( 90 % )	72 ( 90 % )	69 ( 86.25 % )	
				> 15 (n = 59)	44 ( 74.58 % )	49 ( 83.05 % )	54 ( 91.53 % )	53 ( 89.83 % )	
			Uveitis patients on IMT/year	< 300 (n = 85)	64 ( 75.29 % )	73 ( 85.88 % )	74 ( 87.06 % )	73 ( 85.88 % )	
				≥ 300 (n =54)	42 ( 77.78 % )	48 ( 88.89 % )	52 ( 96.3 % )	49 ( 90.74 % )	
<b>CONVENTIONAL IMT</b>		To be started	Years of experience in uveitis	≤ 15 (n = 80)	44 ( 55 % )	19 ( 23.75 % )	6 ( 7.5 % )	3 ( 3.75 % )	
				> 15 (n = 59)	38 ( 64.41 % )	17 ( 28.81 % )	1 ( 1.69 % )	0	
			Uveitis patients on IMT/year	< 300 (n = 85)	52 ( 61.18 % )	22 ( 25.88 % )	4 ( 4.71 % )	2 ( 2.35 % )	
				≥ 300 (n =54)	30 ( 55.56 % )	14 ( 25.93 % )	3 ( 5.56 % )	1 ( 1.85 % )	
			To be maintained	Years of experience in uveitis	≤ 15 (n = 80)	71 ( 88.75 % )	39 ( 48.75 % )	10 ( 12.5 % )	6 ( 7.5 % )
					> 15 (n = 59)	54 ( 91.53 % )	33 ( 55.93 % )	8 ( 13.56 % )	5 ( 8.47 % )
		Uveitis patients on IMT/year		< 300 (n = 85)	75 ( 88.24 % )	43 ( 50.59 % )	14 ( 16.47 % )	7 ( 8.24 % )	
				≥ 300 (n =54)	50 ( 92.59 % )	29 ( 53.7 % )	4 ( 7.41 % )	4 ( 7.41 % )	
		to be decreased	Years of experience in uveitis	≤ 15 (n = 80)	13 ( 16.25 % )	42 ( 52.5 % )	67 ( 83.75 % )	71 ( 88.75 % )	
				> 15 (n = 59)	5 ( 8.47 % )	29 ( 49.15 % )	49 ( 83.05 % )	50 ( 84.75 % )	
			Uveitis patients on IMT/year	< 300 (n = 85)	11 ( 12.94 % )	41 ( 48.24 % )	68 ( 80 % )	75 ( 88.24 % )	
				≥ 300 (n =54)	7 ( 12.96 % )	30 ( 55.56 % )	48 ( 88.89 % )	46 ( 85.19 % )	
		To be stopped	Years of experience in uveitis	≤ 15 (n = 80)	7 ( 8.75 % )	28 ( 35 % )	64 ( 80 % )	72 ( 90 % )	
				> 15 (n = 59)	5 ( 8.47 % )	21 ( 35.59 % )	48 ( 81.36 % )	51 ( 86.44 % )	

		Uveitis patients on IMT/year	< 300 (n = 85)	9 ( 10.59 % )	31 ( 36.47 % )	63 ( 74.12 % )	73 ( 85.88 % )
			≥ 300 (n =54)	3 ( 5.56 % )	18 ( 33.33 % )	49 ( 90.74 % )	50 ( 92.59 % )
<b>BIOLOGICS</b>	To be started	Years of experience in uveitis	≤ 15 (n = 80)	37 ( 46.25 % )	10 ( 12.5 % )	3 ( 3.75 % )	4 ( 5 % )
			> 15 (n = 59)	32 ( 54.24 % )	13 ( 22.03 % )	3 ( 5.08 % )	2 ( 3.39 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	42 ( 49.41 % )	11 ( 12.94 % )	3 ( 3.53 % )	4 ( 4.71 % )
			≥ 300 (n =54)	27 ( 50 % )	12 ( 22.22 % )	3 ( 5.56 % )	2 ( 3.7 % )
	To be continued	Years of experience in uveitis	≤ 15 (n = 80)	71 ( 88.75 % )	40 ( 50 % )	12 ( 15 % )	6 ( 7.5 % )
			> 15 (n = 59)	52 ( 88.14 % )	33 ( 55.93 % )	6 ( 10.17 % )	4 ( 6.78 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	72 ( 84.71 % )	42 ( 49.41 % )	14 ( 16.47 % )	8 ( 9.41 % )
			≥ 300 (n =54)	51 ( 94.44 % )	31 ( 57.41 % )	4 ( 7.41 % )	2 ( 3.7 % )
	To be stopped	Years of experience in uveitis	≤ 15 (n = 80)	9 ( 11.25 % )	41 ( 51.25 % )	69 ( 86.25 % )	71 ( 88.75 % )
			> 15 (n = 59)	8 ( 13.56 % )	22 ( 37.29 % )	47 ( 79.66 % )	52 ( 88.14 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	10 ( 11.76 % )	39 ( 45.88 % )	69 ( 81.18 % )	75 ( 88.24 % )
			≥ 300 (n =54)	7 ( 12.96 % )	24 ( 44.44 % )	47 ( 87.04 % )	48 ( 88.89 % )
<b>TOCILIZUMAB</b>	To be started	Years of experience in uveitis	≤ 15 (n = 80)	44 ( 55 % )	30 ( 37.5 % )	22 ( 27.5 % )	22 ( 27.5 % )
			> 15 (n = 59)	41 ( 69.49 % )	27 ( 45.76 % )	17 ( 28.81 % )	18 ( 30.51 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	50 ( 58.82 % )	31 ( 36.47 % )	22 ( 25.88 % )	23 ( 27.06 % )
			≥ 300 (n =54)	35 ( 64.81 % )	26 ( 48.15 % )	17 ( 31.48 % )	17 ( 31.48 % )
	To be continued	Years of experience in uveitis	≤ 15 (n = 80)	71 ( 88.75 % )	54 ( 67.5 % )	33 ( 41.25 % )	31 ( 38.75 % )
			> 15 (n = 59)	57 ( 96.61 % )	44 ( 74.58 % )	33 ( 55.93 % )	31 ( 52.54 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	76 ( 89.41 % )	55 ( 64.71 % )	40 ( 47.06 % )	37 ( 43.53 % )
			≥ 300 (n =54)	52 ( 96.3 % )	43 ( 79.63 % )	26 ( 48.15 % )	25 ( 46.3 % )
	To switch to	Years of experience in uveitis	≤ 15 (n = 80)	28 ( 35 % )	20 ( 25 % )	21 ( 26.25 % )	24 ( 30 % )
			> 15 (n = 59)	16 ( 27.12 % )	12 ( 20.34 % )	20 ( 33.9 % )	21 ( 35.59 % )
		Uveitis patients on IMT/year	< 300 (n = 85)	31 ( 36.47 % )	21 ( 24.71 % )	25 ( 29.41 % )	29 ( 34.12 % )
			≥ 300 (n =54)	13 ( 24.07 % )	11 ( 20.37 % )	16 ( 29.63 % )	16 ( 29.63 % )

**Table 2B: Consensus guidelines on immunomodulatory therapy in times of COVID-19 in High risk patients – As per geographical region**

			Experts' geographical area	Healthy patient – without contact	Healthy patient – with contact	Sick patient – COVID-19 suspected	Sick patient – COVID-19 positive
<b>ORAL CORTICOSTEROIDS</b>	Patient not on oral corticosteroids	To be started	Asia (n = 44)	32 ( 59.26 % )	11 ( 20.37 % )	1 ( 1.85 % )	1 ( 1.85 % )
			Africa (n = 3)	1 ( 1.85 % )	1 ( 1.85 % )	0	0
			Europe (n = 43)	30 ( 55.56 % )	14 ( 25.93 % )	4 ( 7.41 % )	3 ( 5.56 % )
			North America (n = 34)	27 ( 50 % )	12 ( 22.22 % )	2 ( 3.7 % )	1 ( 1.85 % )
			South America (n =7)	3 ( 5.56 % )	1 ( 1.85 % )	0	0
			Oceania (n = 8)	5 ( 9.26 % )	4 ( 7.41 % )	0	0
	Patient on low dose oral corticosteroids	To be maintained	Asia (n = 44)	40 ( 74.07 % )	18 ( 33.33 % )	4 ( 7.41 % )	2 ( 3.7 % )
			Africa (n = 3)	3 ( 5.56 % )	2 ( 3.7 % )	1 ( 1.85 % )	1 ( 1.85 % )
			Europe (n = 43)	43 ( 79.63 % )	29 ( 53.7 % )	18 ( 33.33 % )	16 ( 29.63 % )
			North America (n = 34)	30 ( 55.56 % )	20 ( 37.04 % )	11 ( 20.37 % )	8 ( 14.81 % )
			South America (n =7)	7 ( 12.96 % )	3 ( 5.56 % )	0	0
			Oceania (n = 8)	6 ( 11.11 % )	5 ( 9.26 % )	2 ( 3.7 % )	1 ( 1.85 % )
	Patient on low dose oral corticosteroids	To be decreased	Asia (n = 44)	9 ( 16.67 % )	30 ( 55.56 % )	39 ( 72.22 % )	41 ( 75.93 % )
			Africa (n = 3)	0	2 ( 3.7 % )	2 ( 3.7 % )	2 ( 3.7 % )
			Europe (n = 43)	4 ( 7.41 % )	19 ( 35.19 % )	22 ( 40.74 % )	25 ( 46.3 % )
			North America (n = 34)	6 ( 11.11 % )	15 ( 27.78 % )	26 ( 48.15 % )	29 ( 53.7 % )
			South America (n =7)	1 ( 1.85 % )	4 ( 7.41 % )	7 ( 12.96 % )	7 ( 12.96 % )
			Oceania (n = 8)	2 ( 3.7 % )	5 ( 9.26 % )	7 ( 12.96 % )	7 ( 12.96 % )
	Patient on low dose oral corticosteroids	To be tapered and stopped	Asia (n = 44)	8 ( 14.81 % )	27 ( 50 % )	39 ( 72.22 % )	41 ( 75.93 % )
			Africa (n = 3)	0	0	2 ( 3.7 % )	2 ( 3.7 % )
			Europe (n = 43)	2 ( 3.7 % )	14 ( 25.93 % )	23 ( 42.59 % )	24 ( 44.44 % )
			North America (n = 34)	3 ( 5.56 % )	14 ( 25.93 % )	21 ( 38.89 % )	25 ( 46.3 % )
			South America (n =7)	1 ( 1.85 % )	3 ( 5.56 % )	6 ( 11.11 % )	6 ( 11.11 % )
			Oceania (n = 8)	2 ( 3.7 % )	4 ( 7.41 % )	7 ( 12.96 % )	7 ( 12.96 % )
	Patient on higher dose	To be maintained	Asia (n = 44)	25 ( 46.3 % )	12 ( 22.22 % )	4 ( 7.41 % )	2 ( 3.7 % )

	oral corticosteroids		Africa (n = 3)	2 ( 3.7 % )	1 ( 1.85 % )	0	0	
			Europe (n = 43)	32 ( 59.26 % )	19 ( 35.19 % )	8 ( 14.81 % )	3 ( 5.56 % )	
			North America (n = 34)	20 ( 37.04 % )	8 ( 14.81 % )	4 ( 7.41 % )	5 ( 9.26 % )	
			South America (n =7)	3 ( 5.56 % )	1 ( 1.85 % )	0	0	
			Oceania (n = 8)	4 ( 7.41 % )	2 ( 3.7 % )	1 ( 1.85 % )	0	
		To be decreased	Asia (n = 44)	24 ( 44.44 % )	35 ( 64.81 % )	41 ( 75.93 % )	42 ( 77.78 % )	
			Africa (n = 3)	2 ( 3.7 % )	1 ( 1.85 % )	2 ( 3.7 % )	2 ( 3.7 % )	
			Europe (n = 43)	18 ( 33.33 % )	26 ( 48.15 % )	35 ( 64.81 % )	37 ( 68.52 % )	
			North America (n = 34)	11 ( 20.37 % )	21 ( 38.89 % )	30 ( 55.56 % )	32 ( 59.26 % )	
			South America (n =7)	4 ( 7.41 % )	7 ( 12.96 % )	7 ( 12.96 % )	7 ( 12.96 % )	
		To be tapered and stopped	Oceania (n = 8)	4 ( 7.41 % )	6 ( 11.11 % )	8 ( 14.81 % )	8 ( 14.81 % )	
			Asia (n = 44)	16 ( 29.63 % )	30 ( 55.56 % )	40 ( 74.07 % )	41 ( 75.93 % )	
	Africa (n = 3)		0	1 ( 1.85 % )	3 ( 5.56 % )	3 ( 5.56 % )		
	Europe (n = 43)		8 ( 14.81 % )	14 ( 25.93 % )	27 ( 50 % )	31 ( 57.41 % )		
	North America (n = 34)		4 ( 7.41 % )	16 ( 29.63 % )	26 ( 48.15 % )	28 ( 51.85 % )		
	South America (n =7)		2 ( 3.7 % )	4 ( 7.41 % )	7 ( 12.96 % )	7 ( 12.96 % )		
	IV METHYL PREDNISOLONE		To be started	Oceania (n = 8)	4 ( 7.41 % )	5 ( 9.26 % )	7 ( 12.96 % )	8 ( 14.81 % )
				Asia (n = 44)	23 ( 42.59 % )	7 ( 12.96 % )	1 ( 1.85 % )	1 ( 1.85 % )
Africa (n = 3)				1 ( 1.85 % )	0	0	0	
Europe (n = 43)				21 ( 38.89 % )	6 ( 11.11 % )	4 ( 7.41 % )	3 ( 5.56 % )	
North America (n = 34)				22 ( 40.74 % )	11 ( 20.37 % )	1 ( 1.85 % )	1 ( 1.85 % )	
South America (n =7)				2 ( 3.7 % )	0	1 ( 1.85 % )	1 ( 1.85 % )	
LOCAL CORTICOSTEROIDS	Patient not on oral corticosteroids	To be preferred to systemic therapy	Oceania (n = 8)	4 ( 7.41 % )	1 ( 1.85 % )	0	0	
			Asia (n = 44)	31 ( 57.41 % )	37 ( 68.52 % )	36 ( 66.67 % )	34 ( 62.96 % )	
			Africa (n = 3)	3 ( 5.56 % )	3 ( 5.56 % )	3 ( 5.56 % )	3 ( 5.56 % )	
			Europe (n = 43)	32 ( 59.26 % )	41 ( 75.93 % )	40 ( 74.07 % )	41 ( 75.93 % )	
			North America (n = 34)	26 ( 48.15 % )	27 ( 50 % )	30 ( 55.56 % )	30 ( 55.56 % )	
			South America (n =7)	4 ( 7.41 % )	6 ( 11.11 % )	6 ( 11.11 % )	6 ( 11.11 % )	

	Patient on low dose oral corticosteroids	To be preferred to increasing systemic therapy	Asia (n = 44)	33 ( 61.11 % )	37 ( 68.52 % )	40 ( 74.07 % )	37 ( 68.52 % )
Africa (n = 3)			3 ( 5.56 % )	3 ( 5.56 % )	3 ( 5.56 % )	3 ( 5.56 % )	
Europe (n = 43)			33 ( 61.11 % )	38 ( 70.37 % )	40 ( 74.07 % )	40 ( 74.07 % )	
North America (n = 34)			28 ( 51.85 % )	30 ( 55.56 % )	29 ( 53.7 % )	28 ( 51.85 % )	
South America (n =7)			4 ( 7.41 % )	6 ( 11.11 % )	6 ( 11.11 % )	6 ( 11.11 % )	
Oceania (n = 8)			5 ( 9.26 % )	7 ( 12.96 % )	8 ( 14.81 % )	8 ( 14.81 % )	
<b>CONVENTIONAL IMT</b>	To be started	Asia (n = 44)	32 ( 59.26 % )	12 ( 22.22 % )	3 ( 5.56 % )	1 ( 1.85 % )	
		Africa (n = 3)	1 ( 1.85 % )	0	0	0	
		Europe (n = 43)	19 ( 35.19 % )	8 ( 14.81 % )	2 ( 3.7 % )	2 ( 3.7 % )	
		North America (n = 34)	21 ( 38.89 % )	11 ( 20.37 % )	2 ( 3.7 % )	0	
		South America (n =7)	3 ( 5.56 % )	1 ( 1.85 % )	0	0	
		Oceania (n = 8)	6 ( 11.11 % )	4 ( 7.41 % )	0	0	
	To be maintained	Asia (n = 44)	36 ( 66.67 % )	17 ( 31.48 % )	5 ( 9.26 % )	2 ( 3.7 % )	
		Africa (n = 3)	3 ( 5.56 % )	1 ( 1.85 % )	1 ( 1.85 % )	1 ( 1.85 % )	
		Europe (n = 43)	41 ( 75.93 % )	28 ( 51.85 % )	7 ( 12.96 % )	3 ( 5.56 % )	
		North America (n = 34)	32 ( 59.26 % )	19 ( 35.19 % )	4 ( 7.41 % )	4 ( 7.41 % )	
		South America (n =7)	6 ( 11.11 % )	1 ( 1.85 % )	0	0	
		Oceania (n = 8)	7 ( 12.96 % )	6 ( 11.11 % )	1 ( 1.85 % )	1 ( 1.85 % )	
	To be decreased	Asia (n = 44)	9 ( 16.67 % )	27 ( 50 % )	40 ( 74.07 % )	41 ( 75.93 % )	
		Africa (n = 3)	0	2 ( 3.7 % )	3 ( 5.56 % )	3 ( 5.56 % )	
		Europe (n = 43)	4 ( 7.41 % )	16 ( 29.63 % )	30 ( 55.56 % )	33 ( 61.11 % )	
		North America (n = 34)	4 ( 7.41 % )	17 ( 31.48 % )	29 ( 53.7 % )	29 ( 53.7 % )	
		South America (n =7)	1 ( 1.85 % )	7 ( 12.96 % )	7 ( 12.96 % )	7 ( 12.96 % )	
		Oceania (n = 8)	0	2 ( 3.7 % )	7 ( 12.96 % )	8 ( 14.81 % )	
	To be stopped	Asia (n = 44)	6 ( 11.11 % )	21 ( 38.89 % )	37 ( 68.52 % )	41 ( 75.93 % )	
		Africa (n = 3)	0	0	3 ( 5.56 % )	3 ( 5.56 % )	
		Europe (n = 43)	3 ( 5.56 % )	11 ( 20.37 % )	34 ( 62.96 % )	35 ( 64.81 % )	
		North America (n = 34)	3 ( 5.56 % )	13 ( 24.07 % )	24 ( 44.44 % )	29 ( 53.7 % )	
		South America (n =7)	0	2 ( 3.7 % )	7 ( 12.96 % )	7 ( 12.96 % )	

		Oceania (n = 8)	0	2 ( 3.7 % )	7 ( 12.96 % )	8 ( 14.81 % )
<b>BIOLOGICS</b>	To be started	Asia (n = 44)	25 ( 46.3 % )	5 ( 9.26 % )	1 ( 1.85 % )	1 ( 1.85 % )
		Africa (n = 3)	1 ( 1.85 % )	0	0	0
		Europe (n = 43)	16 ( 29.63 % )	6 ( 11.11 % )	3 ( 5.56 % )	3 ( 5.56 % )
		North America (n = 34)	20 ( 37.04 % )	9 ( 16.67 % )	2 ( 3.7 % )	2 ( 3.7 % )
		South America (n =7)	2 ( 3.7 % )	0	0	0
		Oceania (n = 8)	5 ( 9.26 % )	3 ( 5.56 % )	0	0
	To be continued	Asia (n = 44)	35 ( 64.81 % )	15 ( 27.78 % )	4 ( 7.41 % )	1 ( 1.85 % )
		Africa (n = 3)	2 ( 3.7 % )	1 ( 1.85 % )	0	0
		Europe (n = 43)	43 ( 79.63 % )	31 ( 57.41 % )	7 ( 12.96 % )	4 ( 7.41 % )
		North America (n = 34)	29 ( 53.7 % )	18 ( 33.33 % )	6 ( 11.11 % )	4 ( 7.41 % )
		South America (n =7)	6 ( 11.11 % )	2 ( 3.7 % )	0	0
		Oceania (n = 8)	8 ( 14.81 % )	6 ( 11.11 % )	1 ( 1.85 % )	1 ( 1.85 % )
	To be stopped	Asia (n = 44)	10 ( 18.52 % )	29 ( 53.7 % )	38 ( 70.37 % )	41 ( 75.93 % )
		Africa (n = 3)	1 ( 1.85 % )	2 ( 3.7 % )	3 ( 5.56 % )	3 ( 5.56 % )
		Europe (n = 43)	2 ( 3.7 % )	9 ( 16.67 % )	33 ( 61.11 % )	37 ( 68.52 % )
		North America (n = 34)	4 ( 7.41 % )	16 ( 29.63 % )	28 ( 51.85 % )	28 ( 51.85 % )
		South America (n =7)	0	4 ( 7.41 % )	7 ( 12.96 % )	7 ( 12.96 % )
		Oceania (n = 8)	0	3 ( 5.56 % )	7 ( 12.96 % )	7 ( 12.96 % )
<b>TOCILIZUMAB</b>	To be started	Asia (n = 44)	26 ( 48.15 % )	17 ( 31.48 % )	12 ( 22.22 % )	11 ( 20.37 % )
		Africa (n = 3)	1 ( 1.85 % )	1 ( 1.85 % )	1 ( 1.85 % )	1 ( 1.85 % )
		Europe (n = 43)	25 ( 46.3 % )	18 ( 33.33 % )	15 ( 27.78 % )	16 ( 29.63 % )
		North America (n = 34)	26 ( 48.15 % )	17 ( 31.48 % )	9 ( 16.67 % )	9 ( 16.67 % )
		South America (n =7)	3 ( 5.56 % )	0	1 ( 1.85 % )	1 ( 1.85 % )
		Oceania (n = 8)	4 ( 7.41 % )	4 ( 7.41 % )	1 ( 1.85 % )	2 ( 3.7 % )
	To be continued	Asia (n = 44)	37 ( 68.52 % )	26 ( 48.15 % )	17 ( 31.48 % )	15 ( 27.78 % )
		Africa (n = 3)	3 ( 5.56 % )	1 ( 1.85 % )	1 ( 1.85 % )	1 ( 1.85 % )
		Europe (n = 43)	42 ( 77.78 % )	37 ( 68.52 % )	26 ( 48.15 % )	26 ( 48.15 % )
		North America (n = 34)	32 ( 59.26 % )	24 ( 44.44 % )	17 ( 31.48 % )	15 ( 27.78 % )

		South America (n =7)	7 ( 12.96 % )	4 ( 7.41 % )	2 ( 3.7 % )	2 ( 3.7 % )
		Oceania (n = 8)	7 ( 12.96 % )	6 ( 11.11 % )	3 ( 5.56 % )	3 ( 5.56 % )
	To switch to	Asia (n = 44)	19 ( 35.19 % )	14 ( 25.93 % )	15 ( 27.78 % )	14 ( 25.93 % )
		Africa (n = 3)	0	0	0	0
		Europe (n = 43)	7 ( 12.96 % )	7 ( 12.96 % )	12 ( 22.22 % )	16 ( 29.63 % )
		North America (n = 34)	11 ( 20.37 % )	7 ( 12.96 % )	10 ( 18.52 % )	10 ( 18.52 % )
		South America (n =7)	3 ( 5.56 % )	2 ( 3.7 % )	2 ( 3.7 % )	2 ( 3.7 % )
		Oceania (n = 8)	4 ( 7.41 % )	2 ( 3.7 % )	2 ( 3.7 % )	3 ( 5.56 % )

**Consensus for “No”**

**Consensus for “Yes”**

\*High risk category: patients with uveitis or rheumatologic disease with one of the following risk factors: use of biologics; high doses or multiple immunosuppressives; active systemic disease associated with uveitis; presence of other co-morbidities or multisystem disease including heart, lung and/or renal involvement; neutropenia; smoking; pregnancy; older age; previous history of infection while on IMT